Beamtree faces quarterly lender tests after FY26 covenant breach

Recurring Revenue Growth Masks a Difficult Statutory Year

Beamtree Holdings Limited (ASX:BMT) has delivered the sort of recurring-revenue progress software investors usually welcome, but the balance sheet tells a more complicated story. The company’s designed FY26 Annual Report confirms recurring revenue rose 10% to A$27.5 million, representing 94% of total revenue, while total revenue increased 2% to A$29.2 million.

That improvement did not translate into a stronger operating result. Operating profit fell to A$362,000 from A$725,000, although reported EBITDA recovered to A$310,000 from a A$665,000 loss. The statutory loss after tax widened sharply to A$18.3 million, largely because Beamtree recognised A$13.1 million in non-cash impairments covering goodwill and software assets.

The report’s release is principally a designed annual-report filing: the audited financial statements were lodged with ASX on 28 August. Even so, it provides a fuller account of the strategic reset that was already emerging in Beamtree’s CEO appointment, when Gareth Pye joined from TechnologyOne to lead a more commercially focused phase.

Product Exits Narrow the Investment Case

Beamtree says it is concentrating capital and people on RippleDown diagnostics, its PICQ, PICQ Audit and RISQ coding products, and data benchmarking platforms including Health Roundtable. It has exited the Ability Roundtable and Wellness Roundtable, discontinued its Clinical Decision Support product and is winding down the Ainsoff Deterioration Index.

The impairment charge puts numbers behind that pruning. Goodwill was reduced by A$9.6 million across the Pavilion and Potential(x) cash-generating units, while A$3.6 million of software was written down. The report attributes the software charge partly to the PICQ platform being superseded by internally developed functionality, the cessation of further ICP development pending evidence of product-market fit, the decommissioning of legacy Health Roundtable infrastructure and the decision to discontinue Ainsoff.

BNZ Covenant Breach Shifts FY27 Focus to Cash

More immediately, Beamtree’s funding arrangements remain a key constraint. At 30 June, its monthly recurring revenue growth was 6.30%, below the 10% minimum required under its BNZ facility. BNZ waived that specific breach on 20 August and replaced the growth covenant with quarterly tests covering minimum total revenue, cash operating profit and liquidity.

Beamtree ended FY26 with A$2.5 million in cash and A$3.0 million of undrawn facility capacity, according to the company’s financial highlights. The financial statements also show A$3.288 million of borrowings classified as current because the covenant breach existed at year-end. The directors said the debt should be reclassified as non-current for the period ending 31 December 2026, subject to compliance with the amended covenants.

New Products and Overseas Expansion Face the Proof Test

Management is targeting further recurring revenue growth and cost growth below revenue growth in FY27, without providing detailed revenue or profit guidance. Autonomous Coding Solutions has moved from pilot to production deployment in Canada, while Autonomous Data Entry is being introduced to selected customers. Beamtree also points to continued expansion across the United Kingdom, Canada and Saudi Arabia, although it describes international performance as mixed and says its relationship with Abbott has not yet delivered the expected upside.

The central question is whether the sharper portfolio can convert product activity into enough cash operating profit to satisfy BNZ’s revised tests. The first quarterly covenant test is due on 30 September 2026, making execution rather than presentation the next important chapter in Beamtree’s reset.